Replies to post #177121 on Biotech Values

[DewDiligence]

In light of NVS purchase of GSK oncology portfolio, I'd change company ‘D’ in ONXX SEC filing to GSK rather than PFE…

Does this have any ramifications for future investing decisions, or is it merely a matter of intellectual curiosity?

[DewDiligence]

Why is GSK getting out of oncology? This is what CEO Andrew Witty purportedly said in an interview on CNBC’s ‘Squawk Box’:

http://www.cnbc.com/id/101601134#_gus

“We've been a very newcomer to oncology in the last four or five years... Novartis is world No. 2. This was an opportunity to put our assets that we think are important medicines for patients in the hands of a company with a tremendous distribution network.”